Bachem
  • Products & Services
    • CMC Development
      • Peptide NCEs
      • Oligonucleotide NCEs
    • Commercial API
      • Commercial NCEs
      • Commercial Generics
    • Research & Specialties
      • Catalog Peptides
      • Custom Peptide Synthesis
      • Amino Acid Derivatives
      • Diagnostics
      • Cosmetic Peptides
    • Services & Capabilities
      • Project Management
      • Quality & Regulatory
      • Analytical capabilities
      • GMP Production
      • Research Grade Production
      • Supply & vertical integration
  • About Bachem
    • Company overview
      • Our Purpose
      • Our vision & strategy
      • Our Leadership
      • Our History
      • Our Locations
    • Innovation
      • Innovation matters
      • Innovation collaborations
    • Sustainability
      • People & culture
      • Safeguarding the environment
      • Acting ethically
    • Investors & Media
      • Reports & Presentations
      • Financial events
      • Media Library
      • Press archive
  • News & Events
    • News
    • Events
  • Careers
  • Contact
Select Page
Bachem enters strategic collaboration with Lilly to manufacture oligonucleotide-based drug substances

Bachem enters strategic collaboration with Lilly to manufacture oligonucleotide-based drug substances

Apr 26, 2022 | Ad-hoc, CMC development, Featured news, News, Oligonucleotides

  Strategic collaboration with Lilly to develop innovative and efficient processing solutions for the manufacture of oligonucleotide-based drug substances. The annual order volume has the potential to achieve around CHF 100 million, depending on Bachem reaching...
Knowledge Center
General Conditions
Legal Statement
Privacy Policy
Imprint
Contact
  •  

  •  

  •  

  •  

  •